Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1-504-608-2390

THE EFFICACY OF GARCINIA MANGOSTANA TO REDUCE ENDOTHELIAL DYSFUNCTION AND DYSLIPIDEMIA IN HIGH FRAMINGHAM RISK SCORE PATIENTS

Joint Event on 2nd World Congress on CARDIOLOGY & 39th Annual Congress on MICROBIOLOGY AND MICROBIAL INFECTION
July 23-24, 2018 | Rome , Italy

Aditha Satria, Djanggan Sargowo, Ardian Rizal, M Ryan Ramadhan, Olivia Handayani, Aris Munandar, Muhamad Rizki Fadlan, Puspa Lestari, Dion Setiawan and William Prayogo Susanto

Dr Saiful Anwar General Hospital, Indonesia
Brawijaya University, Indonesia
Center Study of Degeneratif Disease

Posters & Accepted Abstracts : Biomed Res

DOI: 10.4066/biomedicalresearch-C1-003

Abstract:

Background: Endothelial dysfunction and dyslipidemia have an important role in the development of atherosclerotic cardiovascular disease. Garcinia Mangostana is an extract of mangosteen that has anti inflamation, immunomodulator, antioxidant, and anti lipid effect. High level of inflamation, lipid profiles, oxidant markers, and circulating endothelial cell (CEC) with low level of endothelial progenitor cell (EPC) predict poor outcomes of endothelial damage. This study was aimed to compare the efficacy of Garcinia Mangostana to reduce endothelial dysfunction and dyslipidemia in high framingham risk score to be compare with placebo. Parameters measured are inflamatory markers (IL-6, TNF α, HsCRP), CEC, EPC, and lipid profiles (total cholesterol, HDL, LDL, and triglycerides). Methods: A randomized, single blind, placebo-controlled clinical trial was conducted in 90 high framingham risk score patients. Study group consumes Garcinia Mangostana 5x550 mg for three months as an additional therapy of their regular medications and control group consumed placebo. The data was analyzed by paired t-test for parametric data and wilcoxon test for non parametric data. Results: Post tests were performed after Garcinia Mangostana administration for three months. Inflamation parameters in study group (IL-6, IL-1, and HsCRP) concentration was significantly decreased compared with placebo (−90.85±99.29, 3 pg/ml vs. 50.25±140, 52 pg/ml; P=0.000; −12.08±12, 1 pg/ml vs. 10.3±13.4 pg/ml; P=0.000; and −130.5±106, 3 pg/ml vs. -17.1±71, 7 pg/ ml; P=0.000). We also observed significance decrease in total cholesterol, LDL, and HbA1c (−12.52±37.31 mg/dl vs. 1.36±26.25 mg/dl; P=0.05; −18.29±28.6 mg/dl vs. 1.8±18.5 mg/dl; P=0.003; −0.29.±1.1 vs. 0.25±0.78; P=0.012; respectively) when compared to placebo group. There was no difference in HDL, triglycerides and fasting blood glucose. CEC also significantly reduced with increasing of EPC in study group (p=0.000). Conclusion: The result shows that Garcinia Mangostana extract has an efficacy to reduce inflamation (IL-1, IL-6, MDA, and HsCRP), lipid profile, CEC and increase EPC level that reflects an improvement of endothelial function.

PDF HTML

Get the App